For the year ending 2025-12-31, CRMD made $311,709,000 in revenue. $163,055,000 in net income. Net profit margin of 52.31%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenues | 311,709,000 | 43,472,170 | ||
| Cost of sales (exclusive of amortization of intangibles) | 22,089,000 | 3,190,534 | ||
| Amortization of intangibles | 13,872,000 | - | ||
| Gross profit | 275,748,000 | 40,281,636 | ||
| Research and development | 19,333,000 | 3,942,270 | ||
| Selling and marketing | 38,054,000 | 28,736,605 | ||
| General and administrative | 68,220,000 | 29,959,150 | ||
| Total operating expenses | 125,607,000 | 62,638,025 | ||
| Other income | - | 520,000 | ||
| Income (loss) from operations | 150,141,000 | - | ||
| Interest income | 3,846,000 | 2,578,792 | ||
| Foreign exchange transaction loss | -52,000 | -30,788 | ||
| Unrealized gain on marketable security | 5,364,000 | - | ||
| Change in contingent consideration | -6,501,000 | - | ||
| Interest expense | 2,782,000 | 36,405 | ||
| Total other income (expense) | -125,000 | 3,031,599 | ||
| Net income (loss) before income taxes | 150,016,000 | -19,324,790 | ||
| Income tax (benefit) | -13,039,000 | -1,394,770 | ||
| Net income (loss) | 163,055,000 | -17,930,020 | ||
| Unrealized (loss) gain from investments | - | -4,830 | ||
| Foreign currency translation gain | - | 1,368 | ||
| Total other comprehensive gain (loss) | - | -3,462 | ||
| Comprehensive loss | - | -17,933,482 | ||
| Basic EPS | 2.25 | -0.3 | ||
| Diluted EPS | 2.04 | -0.3 | ||
| Basic Average Shares | 72,034 | 58,871,582 | ||
| Diluted Average Shares | 80,308 | 58,871,582 | ||
CorMedix Inc. (CRMD)
CorMedix Inc. (CRMD)